A number of other analysts have also recently weighed in on XOMA. Analysts at Cowen & Co initiated coverage on shares of XOMA Ltd in a research note to investors on Monday. They set an “outperform” rating on the stock. Analysts at Ladenburg Thalmann cut their price target on shares of XOMA Ltd from $9.00 to $4.50 in a research note to investors on Tuesday, March 20th. They now have a “buy” rating on the stock.
Shares of XOMA Ltd traded down 3.09% during mid-day trading on Monday, hitting $2.51. XOMA Ltd has a one year low of $1.04 and a one year high of $3.15. The company’s market cap is $170.9 million.
XOMA Ltd. (XOMA) is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases.